NDRANasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
ENDRA Life Sciences Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$4.75+0.01 (+0.21%)
Close on Oct 19, 2026
- Market cap
- $11.76M
- P/E (TTM)
- –
- Dividend yield
- –
ENDRA Life Sciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Electromedical & Electrotherapeutic Apparatus companies for comparison
Valuation
| Measure | ENDRA Life Sciences | Industry median |
|---|---|---|
| Market Cap | $7.12M | $230.55M |
| Enterprise Value | $5.38M | $202.97M |
| PB Ratio | 1.13 | 3.04 |
| P/TBV Ratio | 1.13 | 4.43 |
Income (trailing twelve months)
| Measure | ENDRA Life Sciences | Industry median |
|---|---|---|
| Operating Income | -$6.65M | -$4.31M |
| Pretax Income | -$5.92M | -$2.37M |
| Net Income | -$5.92M | -$6.57M |
| EBITDA | -$6.61M | -$1.98M |
| EPS (Diluted) | -$5.98 | -$0.08 |
Returns
| Measure | ENDRA Life Sciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -152.0% | -18.2% |
| Return on Assets (ROA) | -110.1% | -13.3% |
| Return on Invested Capital (ROIC) | -248.1% | -3.69% |
| Return on Capital Employed (ROCE) | -92.9% | -9.07% |
Balance sheet
| Measure | ENDRA Life Sciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.74M | $36.66M |
| Net Cash (Debt) | $1.74M | $3.92M |
| Net Cash Per Share | $1.16 | $0.28 |
| Equity (Book Value) | $6.31M | $55.33M |
| Book Value Per Share | $4.21 | $2.87 |
| Tangible Book Value | $6.31M | $10.79M |
| Working Capital | $4.80M | $56.72M |
Financial position
| Measure | ENDRA Life Sciences | Industry median |
|---|---|---|
| Current Ratio | 7.10 | 2.48 |
| Quick Ratio | 2.21 | 1.53 |
Cash flow (trailing twelve months)
| Measure | ENDRA Life Sciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$4.82M | -$566.22K |
Efficiency
| Measure | ENDRA Life Sciences | Industry median |
|---|---|---|
| Profits Per Employee | -$537.88K | -$51.88K |
| Employee Count | 11 | 185 |
Dividends and yields
| Measure | ENDRA Life Sciences | Industry median |
|---|---|---|
| Earnings Yield | -83.0% | -6.88% |
| Buyback Yield | -8.04% | 0.78% |
| Shareholder Yield | -8.04% | 0.80% |
Shares
| Measure | ENDRA Life Sciences | Industry median |
|---|---|---|
| Shares Outstanding | 1,499,840 | 44,302,700 |
| Shares Change (QoQ) | 20.9% | 0.27% |
| Float | 782,325 | 37,462,700 |
| Shares Held by Insiders | 47.8% | 10.5% |
| Shares Held by Institutions | 10.2% | 63.5% |
Scores
| Measure | ENDRA Life Sciences | Industry median |
|---|---|---|
| Altman Z-Score | -19.09 | 1.95 |
| Piotroski F-Score | 3 | 5 |
Calculated by StockData from ENDRA Life Sciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.